- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04403308
ONO-7913 Phase I Study (ONO-7913)
August 1, 2022 updated by: Ono Pharmaceutical Co. Ltd
An Open-label, Uncontrolled, Dose Escalation Study in Patients With Advanced or Metastatic Solid Cancers (ONO-7913-01)
To assess the tolerability, safety, and pharmacokinetics (PK) of ONO-7913 in patients with advanced or metastatic solid cancers and explore its efficacy and biomarkers.
Study Overview
Study Type
Interventional
Enrollment (Actual)
7
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Tokyo
-
Chuo-ku, Tokyo, Japan
- Local Institution
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with histologically or cytologically confirmed advanced or metastatic solid tumors
- ECOG Performance Status of 0-1
- Patients with life expectancy of at least 3 months
Exclusion Criteria:
- Patients with multiple cancers
- Patients with history of serious allergy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ONO-7913 as a Single Agent
|
ONO-7913 will be administered by intravenous continuous infusion during the designated time.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose-limiting toxicities
Time Frame: 28 days
|
Number of participants with a DLT
|
28 days
|
Adverse events
Time Frame: Up to 24 months
|
Assessed by the NCI CTCAE v5.0 criteria
|
Up to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Concentration vs time of ONO-7913 as single dose
Time Frame: Up to 24 months
|
PK profile
|
Up to 24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Kazuhiro Nakabayashi, Ono Pharmaceutical Co. Ltd
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 28, 2020
Primary Completion (Actual)
January 13, 2022
Study Completion (Actual)
January 13, 2022
Study Registration Dates
First Submitted
May 21, 2020
First Submitted That Met QC Criteria
May 26, 2020
First Posted (Actual)
May 27, 2020
Study Record Updates
Last Update Posted (Actual)
August 2, 2022
Last Update Submitted That Met QC Criteria
August 1, 2022
Last Verified
July 1, 2022
More Information
Terms related to this study
Other Study ID Numbers
- ONO-7913-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumor
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Sorrento Therapeutics, Inc.WithdrawnSolid Tumor | Relapsed Solid Tumor | Refractory Tumor
-
RemeGen Co., Ltd.CompletedMetastatic Solid Tumor | Locally Advanced Solid Tumor | Unresectable Solid TumorAustralia
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
Partner Therapeutics, Inc.WithdrawnSolid Tumor | Solid Tumor, AdultUnited States
-
Jazz PharmaceuticalsMerck Sharp & Dohme LLCRecruitingAdvanced Solid Tumor | Metastatic Solid TumorUnited States
-
PharmaEngineNot yet recruitingAdvanced Solid Tumor | Metastatic Solid Tumor
Clinical Trials on ONO-7913
-
Ono Pharmaceutical Co. LtdCompletedVenous ThromboembolismUnited Kingdom
-
Ono Pharmaceutical Co. LtdCompleted
-
Ono Pharmaceutical Co. LtdCompleted
-
Ono Pharmaceutical Co. LtdTerminatedPain | Osteoarthritis, KneePoland, Hungary, Spain, Denmark, United Kingdom
-
Ono Pharma USA IncCompletedIrritable Bowel Syndrome (IBS)United States
-
Ono Pharma USA IncCompletedMajor Depressive DisorderUnited States
-
Ono Pharma USA IncCompleted
-
Ono Pharma USA IncTerminatedChemotherapy-Induced ThrombocytopeniaUnited States, Korea, Republic of, Russian Federation
-
Ono Pharmaceutical Co. LtdCompletedHealthy Post Menopausal WomenUnited Kingdom
-
Ono Pharmaceutical Co. LtdCompleted